Results 131 to 136 of about 1,361 (136)

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study

Neuro-Oncology Advances, 2022
Daphne Haas-Kogan, Sabine Mueller, Ralph Ermoian   +2 more
exaly  

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Lancet, The, 2021
Jaime Rodriguez-Canales, Swati Garg, Tracy Stockley   +2 more
exaly  

WEE1 kinase inhibitor, adavosertib (AZD1775), as a novel potential therapeutic strategy in advanced adrenocortical carcinoma

Endocrine Abstracts, 2023
Mariangela Tamburello, Silviu Sbiera, Weber Justus, Juliane Lippert, Mario Detomas, Marc Philipp Schauer, Hanna Urlaub, Sonja Steinhauer, Otilia Kimpel, Laura-Sophie Landwehr, Hantel Constanze, Sandra Sigala, Cristina Ronchi, Michael Hudecek, Kiseljak-Vassiliades Katja, Martin Fassnacht, Barbara Altieri   +16 more
openaire   +1 more source

Adavosertib targets Cell Cycle Regulator WEE1 and Inhibits Pediatric Neuroblastoma Growth

The Journal of Pharmacology and Experimental Therapeutics
Abel Daartey, Rameswari Chilamakuri, Saurabh Agarwal   +2 more
openaire   +1 more source

Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study

Cancer Treatment and Research Communications
Shunsuke Kondo, Noboru Yamamoto, Kan Yonemori   +2 more
exaly  

Tu1567 ADAVOSERTIB, A WEE1 INHIBITOR, AS A NOVEL SENOLYTICS, TARGETS THE VULNERABILITY OF LIVER CANCER INDUCED BY EPIRUBICIN

Gastroenterology
openaire   +1 more source